Free Cash Flow Yield: 7.87%
Is the free cash flow yield high or low?
The free cash flow yield of 7.87% is 21% below its 5-year average of 10.02%, near the low end of its 5-year range (4.04%–24.10%).
As of Saturday, June 27, 2026. 3.49% above its 12-month average of 7.60%.
GSK Free Cash Flow Yield Chart
GSK Average Free Cash Flow Yield Chart
GSK Current vs Average Free Cash Flow Yield Chart
GSK Free Cash Flow Yield Metrics
FREE CASH FLOW YIELD
7.87%
FREE CASH FLOW YIELD AVG TTM
7.60%
FREE CASH FLOW YIELD AVG 3Y
7.65%
FREE CASH FLOW YIELD AVG 5Y
9.68%
FREE CASH FLOW YIELD AVG 10Y
8.84%
FREE CASH FLOW YIELD AVG 15Y
7.71%
FREE CASH FLOW YIELD AVG 20Y
8.30%
CURRENT VS TTM AVG
+3.49%
CURRENT VS 3Y AVG
+2.90%
CURRENT VS 5Y AVG
-18.71%
CURRENT VS 10Y AVG
-10.97%
CURRENT VS 15Y AVG
+2.10%
CURRENT VS 20Y AVG
-5.12%
GSK Competitors' Free Cash Flow Yield
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GSK plc (GSK) | $105.20B | 7.87% | 7.60% | 7.65% | 9.68% |
| Medtronic plc (MDT)vs › | $103.66B | 5.20% | 4.54% | 4.50% | 4.33% |
| Bristol-Myers Squibb Company (BMY)vs › | $117.46B | 10.13% | 13.18% | 12.29% | 10.98% |
| McKesson Corporation (MCK)vs › | $89.39B | 6.34% | 6.94% | 5.84% | 7.20% |
| HCA Healthcare, Inc. (HCA)vs › | $86.89B | 8.93% | 7.12% | 6.41% | 6.13% |
| Elevance Health Inc. (ELV)vs › | $85.82B | 7.41% | 6.03% | 5.01% | 6.04% |
| Vertex Pharmaceuticals Incorporated (VRTX)vs › | $124.70B | 2.95% | 3.06% | 3.40% | 3.81% |
| Stryker Corporation (SYK)vs › | $127.39B | 3.55% | 3.02% | 2.50% | 2.54% |
| CVS Health Corp. (CVS)vs › | $133.13B | 5.54% | 6.47% | 9.07% | 10.61% |
| Cigna Corporation (CI)vs › | $74.81B | 10.26% | 8.76% | 9.48% | 9.22% |
Yield Comparison
FCF Yield
7.87%
Earnings Yield
8.61%
Dividend Yield
3.51%
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
- Shows free cash flow after capital expenditures relative to market cap
- Can be compared with earnings yield and dividend yield
- Can be compared with the company's historical range
- Can be compared with peers that report positive free cash flow
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
Free Cash Flow Yield Formula & Definition
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Free Cash Flow Yield FAQ
- What is the free cash flow yield for GSK plc (GSK)?
- The free cash flow yield for GSK stock is 7.87%.
- Is GSK plc's free cash flow yield high or low?
- The free cash flow yield of 7.87% is 21% below its 5-year average of 10.02%, near the low end of its 5-year range (4.04%–24.10%).
- What is the TTM average free cash flow yield for GSK plc (GSK)?
- The TTM average free cash flow yield for GSK stock is 7.60%.
- What is the 3Y average free cash flow yield for GSK plc (GSK)?
- The 3Y average free cash flow yield for GSK stock is 7.65%.
- What is the 5Y average free cash flow yield for GSK plc (GSK)?
- The 5Y average free cash flow yield for GSK stock is 9.68%.
- What is the 10Y average free cash flow yield for GSK plc (GSK)?
- The 10Y average free cash flow yield for GSK stock is 8.84%.
- What is the 15Y average free cash flow yield for GSK plc (GSK)?
- The 15Y average free cash flow yield for GSK stock is 7.71%.
- What is the 20Y average free cash flow yield for GSK plc (GSK)?
- The 20Y average free cash flow yield for GSK stock is 8.30%.
GSK Free Cash Flow Yield History
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2026-06-26 | 7.87% |
| 2026-06-25 | 7.96% |
| 2026-06-24 | 8.08% |
| 2026-06-23 | 7.93% |
| 2026-06-22 | 8.14% |
| 2026-06-18 | 8.15% |
| 2026-06-17 | 7.92% |
| 2026-06-16 | 7.91% |
| 2026-06-15 | 7.91% |
| 2026-06-12 | 7.79% |
| 2026-06-11 | 7.81% |
| 2026-06-10 | 8.07% |
| 2026-06-09 | 8.06% |
| 2026-06-08 | 8.16% |
| 2026-06-05 | 8.01% |
| 2026-06-04 | 8.05% |
| 2026-06-03 | 8.31% |
| 2026-06-02 | 8.42% |
| 2026-06-01 | 8.38% |
| 2026-05-29 | 8.17% |
| 2026-05-28 | 8.06% |
| 2026-05-27 | 8.01% |
| 2026-05-26 | 8.02% |
| 2026-05-22 | 8.04% |
| 2026-05-21 | 8.01% |
| 2026-05-20 | 8.13% |
| 2026-05-19 | 8.09% |
| 2026-05-18 | 8.22% |
| 2026-05-15 | 8.31% |
| 2026-05-14 | 8.10% |
| 2026-05-13 | 8.10% |
| 2026-05-12 | 8.11% |
| 2026-05-11 | 8.29% |
| 2026-05-08 | 8.19% |
| 2026-05-07 | 8.18% |
| 2026-05-06 | 8.17% |
| 2026-05-05 | 8.20% |
| 2026-05-04 | 8.11% |
| 2026-05-01 | 8.00% |
| 2026-04-30 | 7.89% |
| 2026-04-29 | 8.03% |
| 2026-04-28 | 15.08% |
| 2026-04-27 | 15.15% |
| 2026-04-24 | 15.08% |
| 2026-04-23 | 14.77% |
| 2026-04-22 | 14.75% |
| 2026-04-21 | 14.64% |
| 2026-04-20 | 14.33% |
| 2026-04-17 | 14.08% |
| 2026-04-16 | 14.37% |
| 2026-04-15 | 14.20% |
| 2026-04-14 | 13.87% |
| 2026-04-13 | 13.93% |
| 2026-04-10 | 14.10% |
| 2026-04-09 | 14.06% |
| 2026-04-08 | 14.31% |
| 2026-04-07 | 14.71% |
| 2026-04-06 | 14.58% |
| 2026-04-02 | 14.49% |
| 2026-04-01 | 14.66% |
| 2026-03-31 | 14.88% |
| 2026-03-30 | 15.15% |
| 2026-03-27 | 15.24% |
| 2026-03-26 | 15.22% |
| 2026-03-25 | 15.02% |
| 2026-03-24 | 15.50% |
| 2026-03-23 | 15.80% |
| 2026-03-20 | 15.85% |
| 2026-03-19 | 15.67% |
| 2026-03-18 | 15.77% |
| 2026-03-17 | 15.38% |
| 2026-03-16 | 15.27% |
| 2026-03-13 | 15.38% |
| 2026-03-12 | 15.13% |
| 2026-03-11 | 14.90% |
| 2026-03-10 | 14.84% |
| 2026-03-09 | 14.79% |
| 2026-03-06 | 15.06% |
| 2026-03-05 | 14.86% |
| 2026-03-04 | 14.45% |
| 2026-03-03 | 14.39% |
| 2026-03-02 | 14.08% |
| 2026-02-27 | 13.89% |
| 2026-02-26 | 14.14% |
| 2026-02-25 | 13.79% |
| 2026-02-24 | 13.89% |
| 2026-02-23 | 13.85% |
| 2026-02-20 | 13.79% |
| 2026-02-19 | 13.50% |
| 2026-02-18 | 13.42% |
| 2026-02-17 | 13.50% |
| 2026-02-13 | 13.93% |
| 2026-02-12 | 14.03% |
| 2026-02-11 | 14.04% |
| 2026-02-10 | 13.97% |
| 2026-02-09 | 13.93% |
| 2026-02-06 | 13.64% |
| 2026-02-05 | 13.89% |
| 2026-02-04 | 14.35% |
| 2026-02-03 | 7.22% |
| 2026-02-02 | 7.34% |
| 2026-01-30 | 7.46% |
| 2026-01-29 | 7.60% |
| 2026-01-28 | 7.69% |
| 2026-01-27 | 7.58% |
| 2026-01-26 | 7.65% |
| 2026-01-23 | 7.84% |
| 2026-01-22 | 7.92% |
| 2026-01-21 | 8.01% |
| 2026-01-20 | 8.08% |
| 2026-01-16 | 7.99% |
| 2026-01-15 | 7.84% |
| 2026-01-14 | 7.58% |
| 2026-01-13 | 7.72% |
| 2026-01-12 | 7.64% |
| 2026-01-09 | 7.64% |
| 2026-01-08 | 7.67% |
| 2026-01-07 | 7.60% |
| 2026-01-06 | 7.62% |
| 2026-01-05 | 7.86% |
| 2026-01-02 | 7.76% |
| 2025-12-31 | 7.85% |
| 2025-12-30 | 7.81% |
| 2025-12-29 | 7.84% |
| 2025-12-26 | 7.84% |
| 2025-12-24 | 7.86% |
| 2025-12-23 | 7.88% |
| 2025-12-22 | 7.92% |
| 2025-12-19 | 7.92% |
| 2025-12-18 | 7.97% |
| 2025-12-17 | 7.91% |
| 2025-12-16 | 7.89% |
| 2025-12-15 | 7.82% |
| 2025-12-12 | 7.89% |
| 2025-12-11 | 7.88% |
| 2025-12-10 | 7.96% |
| 2025-12-09 | 8.14% |
| 2025-12-08 | 7.94% |
| 2025-12-05 | 7.96% |
| 2025-12-04 | 7.93% |
| 2025-12-03 | 7.86% |
| 2025-12-02 | 7.97% |
| 2025-12-01 | 8.16% |
| 2025-11-28 | 8.05% |
| 2025-11-26 | 8.02% |
| 2025-11-25 | 8.10% |
| 2025-11-24 | 8.20% |
| 2025-11-21 | 8.16% |
| 2025-11-20 | 8.35% |
| 2025-11-19 | 8.31% |
| 2025-11-18 | 8.13% |
| 2025-11-17 | 8.10% |
| 2025-11-14 | 8.16% |
| 2025-11-13 | 8.00% |
| 2025-11-12 | 8.01% |
| 2025-11-11 | 7.96% |
| 2025-11-10 | 8.13% |
| 2025-11-07 | 8.26% |
| 2025-11-06 | 8.18% |
| 2025-11-05 | 8.24% |
| 2025-11-04 | 8.22% |
| 2025-11-03 | 8.31% |
| 2025-10-31 | 8.22% |
| 2025-10-30 | 8.20% |
| 2025-10-29 | 8.38% |
| 2025-10-28 | 6.86% |
| 2025-10-27 | 6.84% |
| 2025-10-24 | 6.93% |
| 2025-10-23 | 6.58% |
| 2025-10-22 | 6.77% |
| 2025-10-21 | 6.82% |
| 2025-10-20 | 6.79% |
| 2025-10-17 | 6.83% |
| 2025-10-16 | 6.84% |
| 2025-10-15 | 6.84% |
| 2025-10-14 | 6.79% |
| 2025-10-13 | 6.86% |
| 2025-10-10 | 6.88% |
| 2025-10-09 | 6.90% |
| 2025-10-08 | 6.91% |
| 2025-10-07 | 6.89% |
| 2025-10-06 | 6.90% |
| 2025-10-03 | 6.91% |
| 2025-10-02 | 6.86% |
| 2025-10-01 | 6.58% |
| 2025-09-30 | 6.94% |
| 2025-09-29 | 7.29% |
| 2025-09-26 | 7.52% |
| 2025-09-25 | 7.58% |
| 2025-09-24 | 7.46% |
| 2025-09-23 | 7.40% |
| 2025-09-22 | 7.33% |
| 2025-09-19 | 7.37% |
| 2025-09-18 | 7.43% |
| 2025-09-17 | 7.42% |
| 2025-09-16 | 7.48% |
| 2025-09-15 | 7.43% |
| 2025-09-12 | 7.34% |
| 2025-09-11 | 7.23% |
| 2025-09-10 | 7.40% |
| 2025-09-09 | 7.35% |
| 2025-09-08 | 7.48% |
| 2025-09-05 | 7.40% |
| 2025-09-04 | 7.56% |
| 2025-09-03 | 7.61% |
| 2025-09-02 | 7.69% |
| 2025-08-29 | 7.55% |
| 2025-08-28 | 7.60% |
| 2025-08-27 | 7.51% |
| 2025-08-26 | 7.52% |
| 2025-08-25 | 7.56% |
| 2025-08-22 | 7.46% |
| 2025-08-21 | 7.47% |
| 2025-08-20 | 7.48% |
| 2025-08-19 | 7.56% |
| 2025-08-18 | 7.67% |
| 2025-08-15 | 7.61% |
| 2025-08-14 | 7.64% |
| 2025-08-13 | 7.66% |
| 2025-08-12 | 7.84% |
| 2025-08-11 | 7.95% |
| 2025-08-08 | 7.92% |
| 2025-08-07 | 7.97% |
| 2025-08-06 | 8.16% |
| 2025-08-05 | 8.03% |
| 2025-08-04 | 7.96% |
| 2025-08-01 | 7.98% |
| 2025-07-31 | 8.06% |
| 2025-07-30 | 7.69% |
| 2025-07-29 | 6.41% |
| 2025-07-28 | 6.45% |
| 2025-07-25 | 6.36% |
| 2025-07-24 | 6.32% |
| 2025-07-23 | 6.35% |
| 2025-07-22 | 6.53% |
| 2025-07-21 | 6.68% |
| 2025-07-18 | 6.65% |
| 2025-07-17 | 6.62% |
| 2025-07-16 | 6.31% |
| 2025-07-15 | 6.39% |
| 2025-07-14 | 6.31% |
| 2025-07-11 | 6.31% |
| 2025-07-10 | 6.11% |
| 2025-07-09 | 6.19% |
| 2025-07-08 | 6.28% |
| 2025-07-07 | 6.33% |
| 2025-07-03 | 6.33% |
| 2025-07-02 | 6.27% |
| 2025-07-01 | 6.20% |
| 2025-06-30 | 6.29% |
| 2025-06-27 | 6.26% |
| 2025-06-26 | 6.27% |
| 2025-06-25 | 6.31% |
| 2025-06-24 | 6.25% |
| 2025-06-23 | 6.31% |
| 2025-06-20 | 6.35% |
| 2025-06-18 | 6.25% |
| 2025-06-17 | 6.08% |
| 2025-06-16 | 5.97% |
| 2025-06-13 | 5.91% |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
About GSK plc
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels